Verona Pharma plc
VRNA
株式のランク
#2229
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
株価
$106.91
最終同期: 2025-10-07
時価総額
$9.09B
変化（1日）
0.00%
変化（1年）
0.00%
国
GB
取引 Verona Pharma plc (VRNA)
カテゴリー
Healthcare
Verona Pharma plc（VRNA）の収益
Jun 2025 時点の収益 TTM: $167.65M
Verona Pharma plc の最新の財務報告によると、現在の収益 (TTM) は $167.65M です。2023 年には 0.00 の収益があり、これは 2022 年の $378.87K と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Verona Pharma plc の収益履歴（2005 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $167.65M | 396.46% |
| 2024 | $33.77M | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $378.87K | -98.72% |
| 2021 | $29.58M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 7,429.97% |
US
|
|
| $2.23B | 1,228.93% |
US
|
|
| $15.74B | 9,290.96% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 3,491.50% |
NL
|
